Visit our USA website
Dr Emer MacSweeney, CEO and Medical Director at Re:Cognition Health shared her excitement with the Daily Express about the groundbreaking new Alzheimer’s drugs that are now available to private patients through Re:Cognition Health centres.
Leqembi™ (lecanemab) and Kisunla™ (donanemab) were both delivered as clinical trials through Re:Cognition Health centres. Both treatments were approved by regulators last year, but were not approved to be rolled out through the NHS, due to cost implications. Eligible patients can now access these treatments, which involve either fortnightly or monthly infusions through Re:Cognition Health’s London clinic on New Cavendish Street.
Both drugs are monoclonal antibodies designed to target and clear amyloid-beta plaques in the brain, a hallmark of Alzheimer’s. By reducing these toxic proteins, they help slow cognitive decline and disease progression, offering hope for patients in the early stages of the condition.
Dr MacSweeney shares her excitement for the new medications, “This is an historic breakthrough for people living with Alzheimer’s. This is the first time that it has been possible to treat the underlying disease of Alzheimer’s, and to slow the disease progression and symptoms.”
Similar medications, which work in the same way as Kisunla™ and Leqembi™, are also available through clinical trials through all of Re:Cognition Health’s centres and are completely free to access. Anybody experiencing early signs of Alzheimer’s is urged to get in touch with our team – an early diagnosis is fundamental to treating the disease.
Video courtesy of The Express.
Watch Dr MacSweeney speak to the Express here.
For further information about clinical trials visit: https://recognitionhealth.com/clinical-trials/
To learn more about accessing Leqembi™ and Kisunla™ through private practice: https://recognitionhealth.com/alzheimersmedication/
Read the article in the Express:
https://www.express.co.uk/news/uk/2005874/alzheimers-disease-dementia-drugs-private
